Testosterone is a potential augmentor of antioxidant-induced apoptosis in human prostate cancer cells

Cancer Detection and Prevention

Volumn 26, Issue 2, 2002, Pages 105-113

  Gunawardena, Kushlani ^a   Murray, Darrell K ^a   Meikle, A Wayne ^a  

^a ARUP LABORATORIES   (United States)

Author keywords

ALVA 101; Antioxidants; Apoptosis; DU 145; LNCaP; NF B; PDTC; Prostate cancer; Testosterone

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ANTINEOPLASTIC AGENT; ANTIOXIDANT; DRUG DERIVATIVE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROLINE; PROLINEDITHIOCARBAMATE; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE; THIOCARBAMIC ACID DERIVATIVE;

APOPTOSIS; ARTICLE; CELL CULTURE; CELL DIVISION; CELL NUCLEUS; COMPARATIVE STUDY; DRUG EFFECT; EPITHELIUM CELL; GEL MOBILITY SHIFT ASSAY; GENETICS; HUMAN; MALE; METABOLISM; NEOPLASM; PATHOLOGY; PROSTATE TUMOR; UPREGULATION;

ANDROGENS; ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; APOPTOSIS; CELL DIVISION; CELL NUCLEUS; ELECTROPHORETIC MOBILITY SHIFT ASSAY; EPITHELIAL CELLS; HUMANS; MALE; NEOPLASMS, HORMONE-DEPENDENT; NF-KAPPA B; PROLINE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; TESTOSTERONE; THIOCARBAMATES; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 0036913785     PISSN: 0361090X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0361-090X(02)00036-3     Document Type: Article

References (52)

1. Adzick NS, Lorenz HP. Cells, matrix, growth factors, and the surgeon. The biology of scarless fetal wound repair. Ann Surg 1994;220:10-8.
2. Battegay EJ. Angiogenesis: Mechanistic insights, neovascular diseases and therapeutic prospects. J Mol Med 1995;73:333-46.
3. Cox DA. Transforming growth factor-β3. Cell Biol Int 1995;196:357-71.
4. Floege J, Eng E, Young BA, et al. Factors involved in the regulation of mesangial cell proliferation in vitro and in vivo. Kidney Int Suppl. 1993;39:S-47-S-54.
5. Gressner AM. Activation of proteoglycan synthesis in injured liver: A brief review of molecular and cellular aspects. Eur J Clin Chem Clin Biochem 1994;32:225-37.
6. Harris SE, Harris MA, Mahy P, et al. Expression of bone morphogenetic protein messenger RNAs by normal rat and human prostate and prostate cancer cells. Prostate 1994;24:204-11.
7. Iseki S, Osumi-Yamashita N, Miyazono K, et al. Localizaton of transforming growth factor-β type I and type II receptors in mouse development. Exp Cell Res 1995;219:339-47.
8. Liu XH, Wiley HS, Meikle AW. Androgens regulate proliferation of human prostate cancer cells in culture by increasing transforming growth factor-α (TGF-α) and epidermal growth factor (EGF)/TGF-α receptor. J Clin Endocrinol Metab 1993;77:1472-8.
9. Meikle AW, Smith J. Epidemiology of prostate cancer. Urol Clin North Am 1990;17:709-18.
10. Morton DM, Barrack ER. Modulation of transforming growth factor β1 effects on prostate cancer cell proliferation by growth factors and extracellular matrix. Cancer Res 1995;55:2596-602.
11. Steiner MS. Role of peptide growth factors in the prostate: A review. Urology 1993;42:99-110.
12. Sunderkotter C, Goebeler M, Schulze Osthoff K, et al. Macrophage-derived angiogenesis factors. Pharmacol Ther 1991;51:195-216.
13. Sunderkotter C, Steinbrink K, Goebeler M, et al. Macrophages and angiogenesis. J Leukoc Biol 1994;55:410-22.
14. Thesleff I, Vaahtokari A, Partanen AM. Regulation of organogenesis. Common molecular mechanisms regulating the development of teeth and other organs. Int J Dev Biol 1995;39:35-50.
15. Timme TL, Truong LD, Slawin KM, et al. Mesenchymal-epithelial interactions and transforming growth factor-β1 expression during normal and abnormal prostatic growth. Microsc Res Techol 1995;30:333-41.
16. Wall NA, Hogan BL. TGF-β related genes in development. Curr Opin Genet Dev 1994;4:517-22.
17. Yoshikawa H, Takaoka K. Bone remodelling and its regulators. Nippon Rinsho 1994;52:2262-7.
18. Meikle AW, Stanish WM. Familial prostatic cancer risk and low testosterone. J Clin Endocrinol Metab 1982;54:1104-8.
19. Carter BS, Bova GS, Beaty TH, et al. Hereditary prostate cancer: Epidemiologic and clinical features. J Urol 1993;150:797-802.
20. McWhorter WP, Hernandez AD, Meikle AW, et al. A screening study of prostate cancer in high risk families. J Urol 1992;148:826-8.
21. Parker SL, Tong T, Bolden S, et al. Cancer statistics. Ca Cancer J Clin 1997;47:5-27.
22. Meikle A, Swope R, Yin D, et al. Transforming growth factor β-1 and β-2 and type II receptor functional regulation of ALVA-101 human prostate cancer cells. Metabolism 1999;48:1075-81.
23. Nakajima Y, DelliPizzi A, Mallouh C. Effect of tumor necrosis factor-α and interferon-γ on the growth of human prostate cancer cell lines. Urol Res 1995;23:205-10.
24. Vassalli P. The pathophysiology of tumor necrosis factors. Annu Rev Immunol 1992;10:411-52.
25. Kyprianou N, Bains AK, Jacobs SC. Induction of apoptosis in androgen-independent human prostate cancer cells undergoing thymineless death. Prostate 1994;25:66-75.
26. Kyprianou N, Tu H, Jacobs SC. Apoptotic versus proliferative activities in human benign prostatic hyperplasia. Hum Pathol 1996;27:668-75.
27. Beg AA, Baltimore D. An essential role for NF-κB in preventing TNF-α-induced cell death. Science 1996;274:782-4.
28. Sumitomo M, Tachibana M, Nakashima J, et al. An essential role for nuclear factor κB in preventing TNF-α induced cell death in prostate cancer cells. J Urol 1999;161:674-9.
29. Siebenlist U, Franzoso G, Brown K. Structure, regulation and function of NF-κB. Annu Rev Cell Biol 1994;10:405-55.
30. Van Antwerp DJ, Martin SJ, Kafri T, et al. Suppression of TNF-α-induced apoptosis by NF-κB. Science 1996;274:787-9.
31. Wang CY, Mayo MW, Baldwin Jr AS. TNF- and cancer therapy-induced apoptosis: Potentiation by inhibition of NF-κB. Science 1996;274:784-7.
32. Okamoto T, Watanabe N, Yamauchi N, et al. Endogenous tumor necrosis factor exerts its protective function intracellularly against the cytotoxicity of exogenous tumor necrosis factor. Cancer Res 1992;52:5278-81.
33. Safrit JT, Bonavida B. Sensitivity of resistant human tumor cell lines to tumor necrosis factor and adriamycin used in combination: Correlation between down-regulation of tumor necrosis factor-messenger RNA induction and overcoming resistance. Cancer Res 1992;52:6630-7.
34. Averboukh L, Liang P, Kantoff PW, et al. Regulation of S100P expression by androgen. Prostate 1996;29:350-5.
35. Sato N, Sadar MD, Bruchovsky N. Androgenic induction of prostate-specific antigen gene is repressed by protein-protein interaction between the androgen receptor and AP-1/c-Jun in the human prostate cancer cell line LNCaP. J Biol Chem 1997;272:17485-94.
36. Keller ET, Chang C, Ershler WB. Inhibition of NF-κB activity through maintenance of IκBα levels contributes to dihydrotestosterone-mediated repression of the interleukin-6 promoter. J Biol Chem 1996;271:26267-75.
37. Gunawardena K, Murray DK, Meikle AW. Vitamin E and other antioxidants inhibit human prostate cancer cells through apoptosis. Prostate 2000;44:287-95.
38. Dignam JD, Lebovitz RM, Roeder RG. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res 1983;11:1475-89.
39. Taplin ME, Bubley GJ, Shuster TD, et al. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. New Engl J Med 1995;332:1393-8.
40. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;227:680-5.
41. Kirschenbaum A, Ren M, Levine AC. Enhanced androgen sensitivity in serum-free medium of a subline of the LNCaP human prostate cancer cell line. Steroids 1993;58:439-44.
42. Krongrad A, Wilson CM, Wilson JD, et al. Androgen increases androgen receptor protein while decreasing receptor mRNA in LNCaP cells. Mol Cell Endocrinol 1991;76:79-88.
43. Fair WR, Fleshner NE, Heston W. Cancer of the prostate: A nutritional disease? Urology 1997;50:840-8.
44. Clark LC, Combs Jr GF, Turnbull BW, et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA 1996;276:1957-63.
45. Gann PH, Ma J, Giovannucci E, et al. Lower prostate cancer risk in men with elevated plasma lycopene levels: Results of a prospective analysis. Cancer Res 1999;59:1225-30.
46. Heinonen OP, Albanes D, Virtamo J, et al. Prostate cancer and supplementation with α-tocopherol and β-carotene: Incidence and mortality in a controlled trial. J Natl Cancer Inst 1998;90:440-6.
47. Tang DG, Porter AT. Target to apoptosis: A hopeful weapon for prostate cancer. Prostate 1997;32:284-93.
48. Kuiper GGJM, De Ruiter PE, Brinkmann AO. Androgen receptor heterogeneity in LNCaP cells is caused by a hormone independent phosphorylation step. J Steroid Biochem Mol Biol 1992;41:697-700.
49. Suzuki H, Sato N, Watabe Y, et al. Androgen receptor gene mutations in human prostate cancer. J Steroid Biochem Mol Biol 1993;46:759-65.
50. Veldscholte J, Berrevoets CA, Ris-Stalpers C, et al. The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens. J Steroid Biochem Mol Biol 1992;41:665-9.
51. Stubbs AP, Lalani EN, Stamp GW, et al. Second messenger up-regulation of androgen receptor gene transcription is absent in androgen insensitive human prostatic carcinoma cell lines PC-3 and DU-145. FEBS Lett 1996;383:237-40.
52. Tilley WD, Wilson CM, Marcelli M, et al. Androgen receptor gene expression in human prostate carcinoma cell lines. Cancer Res 1990;50:5382-6.